# Processa Pharmaceuticals Inc. (PCSA)

Source: https://www.quantisnow.com/company/PCSA
Generated: 2026-11-07T20:38:02.540Z

- Ticker: PCSA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001533743
- Website: processapharmaceuticals.com

## About

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.

## Latest PCSA news and filings

- 2026-11-05 13:14 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-processa-pharmaceuticals-inc-6774948)
- 2026-11-05 13:11 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-processa-pharmaceuticals-inc-6774942)
- 2026-11-05 13:10 UTC [SEC Form 8-K] [Processa Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/processa-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-6774941)
- 2026-11-05 13:00 UTC [Conference Announcement] [Processa Pharmaceuticals to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-6774811)
- 2026-11-04 13:10 UTC [SEC Form 8-K] [Processa Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/processa-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-other-6771502)
- 2026-11-04 13:00 UTC [Processa Pharmaceuticals Announces Key Leadership Appointments](https://www.quantisnow.com/insight/processa-pharmaceuticals-announces-key-leadership-appointments-6771430)
- 2026-10-29 12:46 UTC [SEC Form 8-K] [SEC Form 8-K filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-processa-pharmaceuticals-inc-6762851)
- 2026-10-29 12:00 UTC [Leadership Update] [Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics](https://www.quantisnow.com/insight/processa-pharmaceuticals-announces-corporate-and-pipeline-progress-following-acquisition-of-6762637)
- 2026-10-26 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-processa-pharmaceuticals-inc-6756796)
- 2026-10-22 20:37 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-processa-pharmaceuticals-inc-6755410)
- 2026-10-09 20:55 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-processa-pharmaceuticals-inc-6743128)
- 2026-10-09 20:03 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-processa-pharmaceuticals-inc-6742841)
- 2026-10-09 20:02 UTC [SEC Form S-3] [SEC Form S-3 filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-processa-pharmaceuticals-inc-6742823)
- 2026-10-05 11:21 UTC [SEC Form 8-K] [Amendment: Processa Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-processa-pharmaceuticals-inc-filed-sec-form-8-k-financial-statements-6735901)
- 2026-09-01 11:00 UTC [Conference Announcement] [Processa Pharmaceuticals to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences-6700448)
- 2026-08-11 20:21 UTC [SEC Form 4] [Chief Executive Officer Ng George K converted options into 1,600 shares, increasing direct ownership by 10% to 17,092 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-ng-george-k-converted-options-into-1600-6676022)
- 2026-08-04 21:25 UTC [SEC Form 8-K] [SEC Form 8-K filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-processa-pharmaceuticals-inc-6663185)
- 2026-07-31 01:49 UTC [SEC Form 4] [SEC Form 4 filed by Director Gujrathi Sheila](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gujrathi-sheila-6656803)
- 2026-07-31 01:46 UTC [SEC Form 3] [SEC Form 3 filed by new insider Gujrathi Sheila](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-gujrathi-sheila-6656802)
- 2026-07-29 11:35 UTC [SEC Form 8-K] [Processa Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/processa-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-6652720)
- 2026-07-29 11:30 UTC [PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS](https://www.quantisnow.com/insight/processa-pharmaceuticals-inc-announces-acquisition-of-vidya-therapeutics-inc-and-6652694)
- 2026-07-29 00:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Yorke Justin W](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-yorke-justin-w-6652273)
- 2026-07-29 00:29 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Skibsted Russell](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-skibsted-russell-6652269)
- 2026-07-29 00:27 UTC [SEC Form 4] [SEC Form 4 filed by Director Pannu Geraldine](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-pannu-geraldine-6652262)
- 2026-07-29 00:26 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Ng George K](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-ng-george-6652261)
- 2026-07-29 00:25 UTC [SEC Form 4] [SEC Form 4 filed by Director Neal James R](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-neal-james-r-6652259)
- 2026-07-29 00:23 UTC [SEC Form 4] [SEC Form 4 filed by Chief Business - Strategy Off Lin Patrick](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-business---strategy-off-6652257)
- 2026-07-29 00:22 UTC [SEC Form 4] [SEC Form 4 filed by Chief Administrative Officer Guy Wendy](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-administrative-officer-guy-wendy-6652255)
- 2026-07-29 00:19 UTC [SEC Form 4] [SEC Form 4 filed by Director Baluch Khoso](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-baluch-khoso-6652253)
- 2026-07-01 20:20 UTC [Insider Buy] [Chief Administrative Officer Guy Wendy bought $4,701 worth of shares (2,436 units at $1.93), increasing direct ownership by 20% to 14,394 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-administrative-officer-guy-wendy-bought-4701-worth-of-shares-6623057)
- 2026-07-01 20:19 UTC [Insider Buy] [Chief Business - Strategy Off Lin Patrick bought $4,065 worth of shares (2,106 units at $1.93), increasing direct ownership by 19% to 13,113 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-business---strategy-off-lin-patrick-bought-4065-worth-6623043)
- 2026-07-01 20:19 UTC [Insider Buy] [Chief Executive Officer Ng George K bought $5,900 worth of shares (3,057 units at $1.93), increasing direct ownership by 25% to 15,492 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-ng-george-k-bought-5900-worth-of-6623030)
- 2026-07-01 20:17 UTC [Insider Buy] [Chief Financial Officer Skibsted Russell bought $6,325 worth of shares (3,277 units at $1.93), increasing direct ownership by 24% to 16,689 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-skibsted-russell-bought-6325-worth-of-shares-6623019)
- 2026-07-01 20:16 UTC [Insider Buy] [Pres. Research & Development Young David bought $4,885 worth of shares (2,531 units at $1.93), increasing direct ownership by 13% to 21,729 units (SEC Form 4)](https://www.quantisnow.com/insight/pres-research-development-young-david-bought-4885-worth-of-shares-6622999)
- 2026-06-30 20:49 UTC [SEC Form 4] [Director Yorke Justin W converted options into 203 shares, increasing direct ownership by 135% to 353 units (SEC Form 4)](https://www.quantisnow.com/insight/director-yorke-justin-w-converted-options-into-203-shares-increasing-6621124)
- 2026-06-30 20:48 UTC [SEC Form 4] [Director Pannu Geraldine converted options into 203 shares, increasing direct ownership by 9% to 2,391 units (SEC Form 4)](https://www.quantisnow.com/insight/director-pannu-geraldine-converted-options-into-203-shares-increasing-direct-6621116)
- 2026-06-30 20:47 UTC [SEC Form 4] [Director Neal James R converted options into 203 shares, increasing direct ownership by 25% to 1,021 units (SEC Form 4)](https://www.quantisnow.com/insight/director-neal-james-r-converted-options-into-203-shares-increasing-6621112)
- 2026-06-30 20:46 UTC [SEC Form 4] [Director Baluch Khoso converted options into 203 shares, increasing direct ownership by 9% to 2,528 units (SEC Form 4)](https://www.quantisnow.com/insight/director-baluch-khoso-converted-options-into-203-shares-increasing-direct-6621102)
- 2026-06-18 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Processa Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-processa-pharmaceuticals-inc-6608572)
- 2026-06-16 20:24 UTC [Insider Buy] [Pres. Research & Development Young David bought $4,589 worth of shares (2,067 units at $2.22), increasing direct ownership by 12% to 19,198 units (SEC Form 4)](https://www.quantisnow.com/insight/pres-research-development-young-david-bought-4589-worth-of-shares-6604884)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PCSA
- Earnings history: https://www.quantisnow.com/earnings/PCSA
- Dividend history: https://www.quantisnow.com/dividends/PCSA
- Insider transactions: https://www.quantisnow.com/insiders/PCSA
- Options chain: https://www.quantisnow.com/options/PCSA
- SEC 8-K filings only: https://www.quantisnow.com/company/PCSA/8-k
- RSS and alerts for PCSA: https://www.quantisnow.com/docs/rss-feeds.md